AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31381147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily on days 2‐21 every 3 weeks for up to 120 weeks combined with carboplatin and paclitaxel.
Number of subjects: 1366
Study 31381147 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with carboplatin and paclitaxel.
Number of subjects: 1366
Study 29298726 — intervention group
Group type: EXPERIMENTAL
Intervention: BMAC-PRP injection
Number of subjects: 24
Study 29298726 — intervention group
Group type: COMPARATOR
Intervention: Rotator cuff exercise
Number of subjects: 24
Study 27421729 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + 42 KKW moderate intensity
Number of subjects: 237
Study 27421729 — intervention group
Group type: COMPARATOR
Intervention: High amount (67 KKW)/moderate intensity
Number of subjects: 237
Study 27421729 — intervention group
Group type: COMPARATOR
Intervention: High amount (67 KKW)/vigorous intensity
Number of subjects: 237
Study 27421729 — intervention group
Group type: COMPARATOR
Intervention: Low amount (42 KKW)/moderate intensity
Number of subjects: 237
Study 25394847 — intervention group
Group type: EXPERIMENTAL
Intervention: Di'ao Xin Xue Kang (XXK) capsule
Number of subjects: 733
Study 25394847 — intervention group
Group type: COMPARATOR
Intervention: Compound Danshen (CDS) tablet
Number of subjects: 733
Study 22842953 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin 0.075 % 3 times daily for 6 weeks
Number of subjects: 130
Study 20884122 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 21
Study 20884122 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 75 mg/kg
Number of subjects: 21
Study 18172274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide (200 mg/day orally for 12 months)
Number of subjects: 149
Study 18172274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 18172274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 149
Study 16983834 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon Beam Coagulation (ABC)
Number of subjects: 50
Study 16983834 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocoagulation
Number of subjects: 50
Study 14524649 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model with clinical pharmacists
Number of subjects: 125
Study 14524649 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study 10836286 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg in the morning and evening, increased to 75 mg twice daily after 4 weeks
Number of subjects: 84
Study 10836286 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg in the morning and placebo in the evening, increased to 20 mg twice daily after 4 weeks
Number of subjects: 84
Study 8925479 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon green laser (AGL) treatment
Number of subjects: 191
Study 8925479 — intervention group
Group type: COMPARATOR
Intervention: Krypton red laser (KRL) treatment
Number of subjects: 191
Study 8925479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AGL and KRL treatments
Number of subjects: 191
Study 1806404 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 antagonist (chlorpheniramine 4 mg)
Number of subjects: 0
Study 1806404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6761370 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide orally daily
Number of subjects: 38
Study 6761370 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg slow-release furosemide orally daily
Number of subjects: 38
Study 31307381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 10591
Study 31307381 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 10591
Study 28742614 — intervention group
Group type: EXPERIMENTAL
Intervention: OC + SOCK
Number of subjects: 41
Study 28742614 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 41
Study 28742614 — intervention group
Group type: EXPERIMENTAL
Intervention: OC
Number of subjects: 41
Study 27842565 — intervention group
Group type: COMPARATOR
Intervention: Standard care (parenteral morphine at 0.1 mg/kg)
Number of subjects: 0
Study 27842565 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus a landmark-guided fascia iliaca compartment block (FICB)
Number of subjects: 0
Study 27842565 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus an US-guided femoral nerve block
Number of subjects: 0
Study 24113851 — intervention group
Group type: COMPARATOR
Intervention: No AF group
Number of subjects: 80
Study 24113851 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxysmal AF
Number of subjects: 80
Study 24113851 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AF
Number of subjects: 80
Study 24113851 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-standing AF
Number of subjects: 80
Study 24113851 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent and long-standing AF
Number of subjects: 80
Study 22515638 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark II (HUI2)
Number of subjects: 2053
Study 22515638 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark III (HUI3)
Number of subjects: 2053
Study 22515638 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling Thermometer (FT)
Number of subjects: 2053
Study 22515638 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark II (HUI2) and Health Utilities Index Mark III (HUI3)
Number of subjects: 2053
Study 21207918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NovaMin
Number of subjects: 66
Study 21207918 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NovaMin
Number of subjects: 66
Study 21207918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 17763365 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cardioversion after therapeutic anticoagulation
Number of subjects: 0
Study 17763365 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation prior to cardioversion
Number of subjects: 0
Study 16166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 731
Study 16166415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 12897994 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 lipid emulsion
Number of subjects: 10
Study 12897994 — intervention group
Group type: COMPARATOR
Intervention: omega-6 lipid emulsion
Number of subjects: 10
Study 10539780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-dense foods (enriched with micronutrients, 25-100% of RDA)
Number of subjects: 145
Study 10539780 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (skill training including strength, endurance, coordination, and flexibility)
Number of subjects: 145
Study 10539780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nutrient-dense foods and exercise
Number of subjects: 145
Study 10539780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 145
Study 8837185 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection femoral 3-in-1 nerve block with 20 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 33
Study 8837185 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral 3-in-1 nerve block
Number of subjects: 33
Study 8837185 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 33
Study 1360803 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg bolus followed by normal saline infusion
Number of subjects: 42
Study 1360803 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 500 micrograms/kg bolus followed by esmolol 300 micrograms/kg/min infusion
Number of subjects: 42
Study 1360803 — intervention group
Group type: COMPARATOR
Intervention: Normal saline bolus followed by normal saline infusion
Number of subjects: 42
Study 6386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NI) 5, 10, 20 mg
Number of subjects: 15
Study 6386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (AC) 200 mg
Number of subjects: 15
Study 6386007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NI (10 mg three times a day) and AC (200 mg three times a day)
Number of subjects: 15
Study 6386007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30515646 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper group (UG) patients who spared the glottic larynx
Number of subjects: 71
Study 30515646 — intervention group
Group type: COMPARATOR
Intervention: Lower group (LG) patients who did not spare the glottic larynx
Number of subjects: 71
Study 30201602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health eClinic (MHeC) online assessment
Number of subjects: 204
Study 30201602 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face assessment by a Youth Access Clinician
Number of subjects: 204
Study 26825264 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly responsive virtual human (avatar) programmed to be highly responsive (high contingency)
Number of subjects: 61
Study 26825264 — intervention group
Group type: COMPARATOR
Intervention: Non-responsive virtual human (avatar) programmed to be not responsive (low contingency)
Number of subjects: 61
Study 26825264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (high and low contingency)
Number of subjects: 61
Study 24876916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein supplementation
Number of subjects: 150
Study 23338258 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrushing after exposure to acid fruit juices
Number of subjects: 50
Study 23338258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrushing after exposure to acid fruit juices
Number of subjects: 50
Study 23338258 — intervention group
Group type: COMPARATOR
Intervention: Acid fruit juices (kiwifruit, starfruit, green apple, pineapple, acerolla)
Number of subjects: 50
Study 20496852 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fluoride toothpaste technique (2 cm toothpaste, brush for 2 min, swish for 30 sec, no rinsing or eating/drinking for 2 hr)
Number of subjects: 175
Study 20496852 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride toothpaste (no additional instructions)
Number of subjects: 175
Study 20496852 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fluoride toothpaste technique
Number of subjects: 175
Study 20496852 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride toothpaste
Number of subjects: 175
Study 18572319 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 36
Study 18572319 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 36
Study 18572319 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 36
Study 18572319 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy controls)
Number of subjects: 36
Study 15752374 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg single-dose pitavastatin in Child-Pugh grade A
Number of subjects: 12
Study 15752374 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg single-dose pitavastatin in Child-Pugh grade B
Number of subjects: 12
Study 15752374 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 12
Study 12450962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 10
Study 12450962 — intervention group
Group type: COMPARATOR
Intervention: Dose increase
Number of subjects: 10
Study 11196123 — intervention group
Group type: EXPERIMENTAL
Intervention: CRVO
Number of subjects: 384
Study 11196123 — intervention group
Group type: EXPERIMENTAL
Intervention: BRVO
Number of subjects: 384
Study 11196123 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 384
Study 7933492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: ETCO2 40 mmHg
Number of subjects: 15
Study 7933492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: ETCO2 30 mmHg
Number of subjects: 15
Study 7933492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III: ETCO2 20 mmHg (hyperventilated group)
Number of subjects: 15
Study 2971506 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral pills, progestogen‐only oral pills, vaginal ring
Number of subjects: 5
Study 2971506 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot‐medroxyprogesterone acetate (DMPA)
Number of subjects: 5
Study 2971506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 5
Study 29978186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilioretinal artery present
Number of subjects: 3647
Study 28254158 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 41
Study 28254158 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 41
Study 24636956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitted foot orthoses (FOs) with customised chair-side corrections
Number of subjects: 60
Study 24636956 — intervention group
Group type: COMPARATOR
Intervention: Control foot orthoses made without corrections
Number of subjects: 60
Study 22541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 25235
Study 22541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 25235
Study 22541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers without COPD
Number of subjects: 25235
Study 22541719 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers who quit more than 10 years ago
Number of subjects: 25235
Study 22541719 — intervention group
Group type: COMPARATOR
Intervention: Participants with COPD
Number of subjects: 25235
Study 20420959 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal draw-in manoeuvre in combination with ankle dorsiflexion
Number of subjects: 40
Study 20420959 — intervention group
Group type: COMPARATOR
Intervention: Abdominal draw-in manoeuvre alone
Number of subjects: 40
Study 19045963 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-oriented couples therapy (COCT)
Number of subjects: 60
Study 19045963 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 60
Study 19045963 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 60
Study 15914517 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warfarin (Apo-warfarin)
Number of subjects: 7
Study 15914517 — intervention group
Group type: COMPARATOR
Intervention: Coumadin (control group)
Number of subjects: 7
Study 12971525 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine-related research protocols
Number of subjects: 1668
Study 10489822 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 40
Study 10489822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8791228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet pacifier
Number of subjects: 42
Study 8791228 — intervention group
Group type: COMPARATOR
Intervention: Latex pacifier
Number of subjects: 42
Study 8791228 — intervention group
Group type: COMPARATOR
Intervention: Maternal heartbeat sounds
Number of subjects: 42
Study 1346963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beta 2-agonists (higher doses)
Number of subjects: 0
Study 1346963 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of inhaled beta 2-agonists
Number of subjects: 0
Study 1346963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (additional therapy)
Number of subjects: 0
Study 1346963 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel longer-acting inhaled beta 2-agonists (salmeterol and formoterol)
Number of subjects: 0
Study 6497569 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg twice a day for two weeks)
Number of subjects: 798
Study 6497569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study 6497569 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 798
Study 31115768 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed verification secure framework using CIA standard, blockchain, PSO, and AES techniques.
Number of subjects: 0
Study 31115768 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid model pattern combining RFID and finger vein biometrics.
Number of subjects: 0
Study 31115768 — intervention group
Group type: EXPERIMENTAL
Intervention: Steganography technique based on proposed pattern model.
Number of subjects: 0
Study 29488154 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasiglifam (25 mg oral dose)
Number of subjects: 30
Study 29488154 — intervention group
Group type: COMPARATOR
Intervention: Normal hepatic function (control group)
Number of subjects: 30
Study 26775036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy support present, implementation intention present
Number of subjects: 0
Study 26775036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy support present, implementation intention absent
Number of subjects: 0
Study 26775036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy support absent, implementation intention present
Number of subjects: 0
Study 26775036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy support absent, implementation intention absent
Number of subjects: 0
Study 25584315 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF gel (experimental group I)
Number of subjects: 15
Study 25584315 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF gel and PRF membrane (experimental group II)
Number of subjects: 15
Study 25584315 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (control group)
Number of subjects: 15
Study 22449332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with darbepoetin and G-CSF (n = 41), G-CSF was treated for 3 days at a dose of 10 μg/kg/day, plus a single intravenous injection of 4.5 μg/kg of darbepoetin after coronary angioplasty.
Number of subjects: 60
Study 22449332 — intervention group
Group type: COMPARATOR
Intervention: G-CSF alone (n = 19), treated for 3 days at a dose of 10 μg/kg/day.
Number of subjects: 60
Study 20807664 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg, twice-daily, 7 doses)
Number of subjects: 40
Study 20807664 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (5000 IU, once-daily, 4 doses)
Number of subjects: 40
Study 20807664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (24 mg, twice-daily, 7 doses)
Number of subjects: 40
Study 20807664 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 40
Study 17289734 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and reassurance
Number of subjects: 0
Study 15800321 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiotherapy (40 Gy) followed by surgery (arm A)
Number of subjects: 172
Study 15800321 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy followed by chemoradiotherapy (at least 65 Gy) without surgery (arm B)
Number of subjects: 172
Study 12553109 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily for 28 days
Number of subjects: 92
Study 12553109 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 12553109 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 92
Study 9805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Ordered Pointing Task
Number of subjects: 0
Study 9805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring deficit interpretation
Number of subjects: 0
Study 8594122 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine (277 ± 77 mg daily, given every 12 hr)
Number of subjects: 35
Study 8594122 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) codeine
Number of subjects: 35
Study 1706015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem 300 mg
Number of subjects: 85
Study 1706015 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (25 mg hydrochlorothiazide and 50 mg triamterene)
Number of subjects: 85
Study 6785336 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term chrysotherapy (gold therapy)
Number of subjects: 14
Study 6785336 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 14
Study 6785336 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 14
Study 30343408 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer instruction (PI)
Number of subjects: 317
Study 30343408 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation (SE)
Number of subjects: 317
Study 30343408 — intervention group
Group type: COMPARATOR
Intervention: Peer instruction (PI) and Self-explanation (SE)
Number of subjects: 317
Study 29183324 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar (565 kJ, 7.5 g EAAs, 40% L-leucine)
Number of subjects: 21
Study 29183324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel (477 kJ, 7.5 g EAAs, 40% L-leucine)
Number of subjects: 21
Study 29183324 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 21
Study 25671797 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with the Solitaire FR stent retriever
Number of subjects: 70
Study 25671797 — intervention group
Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 70
Study 24598293 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini decoction (Chinese herb group)
Number of subjects: 60
Study 24598293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (corticoid group)
Number of subjects: 60
Study 24598293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22175445 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative behavioral management (CBM)
Number of subjects: 476
Study 22175445 — intervention group
Group type: COMPARATOR
Intervention: Standard parole (SP)
Number of subjects: 476